Media stories about Biohaven Pharmaceutical (NYSE:BHVN) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.5427787457773 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of brokerages have weighed in on BHVN. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. BidaskClub cut shares of Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Canaccord Genuity began coverage on shares of Biohaven Pharmaceutical in a research report on Friday, December 15th. They set a “buy” rating and a $30.00 price target for the company. Finally, Piper Jaffray Companies set a $48.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, December 11th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $36.14.
Biohaven Pharmaceutical (NYSE:BHVN) traded down $0.69 during midday trading on Friday, hitting $29.71. 419,481 shares of the stock traded hands, compared to its average volume of 421,694. Biohaven Pharmaceutical has a twelve month low of $17.00 and a twelve month high of $39.51. The stock has a market capitalization of $1,050.00 and a price-to-earnings ratio of -5.69.
In other news, VP Kimberly Gentile sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $21.99, for a total value of $109,950.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert Berman sold 160,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total transaction of $4,121,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 983,608 shares of company stock valued at $27,275,749.
ILLEGAL ACTIVITY WARNING: “Biohaven Pharmaceutical (BHVN) Getting Somewhat Favorable News Coverage, Report Finds” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/02/10/biohaven-pharmaceutical-bhvn-getting-somewhat-favorable-news-coverage-report-finds.html.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.